Moderna MRNA shares ended the last trading ... reported encouraging data from a portion of an early-stage study on mRNA-4157/V940, its investigational individualized neoantigen therapy (INT ...

mRNA-4157 is designed to prime the immune system ... before the mRNA vaccine technology showed its worth in the COVID-19 pandemic. MSD and Moderna have said they also intend to start a phase ...

Share price rose after a government website posted details of initiation of a phase II/III study on mRNA-4157/V940, Moderna’s investigational individualized neoantigen therapy (INT), in patients ...

The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

Moderna plans to launch its mRNA cancer vaccine (mRNA-4157) for skin cancer in 2025. It's a personalized cancer vaccine therapy that is combined with Merck & Co.'s (NYSE: MRK) blockbuster Keytruda ...

据悉，Moderna已经公布了其名为mRNA-4157的个体化癌症疫苗的中期数据，该疫苗联合... 智通财经APP获悉，据报道，Moderna(MRNA.US) 计划最早于明年推出一种 ...

The company is making progress on several fronts: Cancer Vaccines: Moderna's mRNA-4157, in combination with Merck's Keytruda, has shown promising results in early-stage trials for melanoma and ...

目前Moderna公司的肿瘤疫苗mRNA-4157已进入临床III期，公司预计其针对黑色素瘤的管线最早有望在2025年实现商业化，中信证券认为mRNA肿瘤疫苗凭借在 ...

Gena Wang’s rating is based on a comprehensive evaluation of Moderna’s strategic adjustments ... upside from the accelerated approval of mRNA-4157 in melanoma has diminished due to FDA ...

据悉，Moderna已经公布了其名为mRNA-4157的个体化癌症疫苗的中期数据，该疫苗联合默沙东(MRK.US)PD-1疗法K药(Keytruda，帕博利珠单抗)用于治疗黑色素瘤。

据悉，Moderna已经公布了其名为mRNA-4157的个体化癌症疫苗的中期数据，该疫苗联合默沙东PD-1疗法K药用于治疗黑色素瘤。今年6月，mRNA-4157联合帕博利珠 ...